Immune Mobilization of Autologous Peripheral Blood Stem Cells Using Interleukin-2 and GM-CSF
Status:
Completed
Trial end date:
2011-04-01
Target enrollment:
Participant gender:
Summary
We postulate that the combination of IL-2 and GM-CSF immunotherapy will efficiently mobilize
autologous peripheral blood stem cells and activated immune effector cells in patients with a
hematologic malignancy. These activated effector cells will improve the immune function of
the graft. These hypotheses will be tested using this proposed clinical trial to mobilize
autologous peripheral blood stem cells pre-transplantation.